GlassScriptPhysician profile
Charles Eric Gambla
NPI 1275573107
$4,923.22
in general payments reported to CMS, 2019-2025
23 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $407 · 2021: $736 · 2022: $620 · 2023: $424 · 2024: $1,100 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,922.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,148.31 | 2019-2025 | |
| Amgen INC. | $327.92 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $236.30 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $182.74 | 2019-2025 | Adbry |
| Genzyme Corporation | $179.30 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $169.89 | 2019-2025 | |
| Janssen Biotech, INC. | $159.64 | 2019-2025 | Tremfya |
| Revance Therapeutics, INC. | $126.96 | 2024 | Daxxify |
| Galderma Laboratories, L.P. | $81.81 | 2021-2024 | |
| Pfizer INC. | $73.79 | 2019-2024 | |
| Ucb, INC. | $55.06 | 2024-2025 | Bimzelx |
| Celgene Corporation | $50.14 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.08 | 2019-2025 | Cabtreo, Targretin, Siliq |
| Lilly USA, LLC | $31.04 | 2019-2025 | Ebglyss |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $25.17 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.98 | 2024 | Ycanth |
| Dusa Pharmaceuticals, INC. | $17.54 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.74 | 2025 | Zoryve |
| Organon LLC | $15.48 | 2024 | |
| Vyne Pharmaceuticals INC. | $15.34 | 2021 | |
| Dermira, INC. | $13.07 | 2019 | |
| Genentech USA, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gambla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.